Real-World Effectiveness of Beta-Blockers versus Other Antihypertensives in Reducing All-Cause Mortality and Cardiovascular Events.

ABSTRACT:

Aim

The aim of the study was to compare the effectiveness of beta-blockers with other antihypertensive classes in reducing all-cause mortality, cardiovascular-related mortality and the risk of cerebrocardiovascular events.

Methods

This noninterventional study was conducted within the UK Clinical Practice Research Datalink. Hypertensive patients who initiated antihypertensive monotherapy were allocated to one of five cohorts: beta-blockers; angiotensin-converting enzyme inhibitors (ACEi); angiotensin II receptor blockers (ARB); calcium channel blockers (CCB); and diuretics. Differences in outcomes were assessed using Cox proportional hazard models with competing risks.

Results

A total of 44,404 patients were prescribed beta-blockers (75% atenolol), 132,545 ACEi, 12,018

SUBMITTER: Foch C 

PROVIDER: S-EPMC9356871 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature